Search

Roche Holding AG

Atidarymo kaina

SektoriusSveikatos priežiūra

302 -2.39

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

298.2

Max

310.4

Pagrindiniai rodikliai

By Trading Economics

Pajamos

6.3B

Pardavimai

31B

P/E

Sektoriaus vid.

29.748

63.778

Dividendų pajamingumas

3.1

Pelno marža

20.347

Darbuotojai

103,249

EBITDA

11B

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.10%

2.39%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

233B

Ankstesnė atidarymo kaina

304.39

Ankstesnė uždarymo kaina

302

Naujienos nuotaikos

By Acuity

26%

74%

67 / 386 reitingas Healthcare

Roche Holding AG Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-03-12 09:23; UTC

Pagrindinės rinkos jėgos

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

2025-01-30 09:36; UTC

Uždarbis

Roche Expects Growth to Continue This Year After Sales, Earnings Beat Forecasts -- Update

2025-01-30 06:32; UTC

Uždarbis

Roche Expects Sales, Earnings Growth After Better-Than-Expected Results

2024-11-26 15:27; UTC

Įsigijimai, susijungimai, perėmimai

Trending: Roche to Buy Poseida Therapeutics for Up to $1.5 Billion

2025-03-31 09:31; UTC

Karštos akcijos

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

2025-03-13 07:46; UTC

Rinkos pokalbiai

Roche's Zealand Pharma Deal Signals Commitment to Obesity Drug Market -- Market Talk

2025-03-12 16:34; UTC

Svarbiausios naujienos

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

2025-03-12 08:51; UTC

Rinkos pokalbiai

Roche's Multiple-Sclerosis Drug Sales Potential Fuels Rating Upgrade -- Market Talk

2025-03-12 08:18; UTC

Rinkos pokalbiai

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

2025-02-13 11:43; UTC

Rinkos pokalbiai

Roche's Growth Fueled by Key Drugs, Promising Pipeline -- Market Talk

2025-01-30 07:56; UTC

Rinkos pokalbiai
Uždarbis

Roche Delivered Solid Results But Diagnostics' Profitability Disappoints -- Market Talk

2025-01-30 06:04; UTC

Uždarbis

Roche Expects 2025 EPS Growth in High Single Digit Range at Constant Currency

2025-01-30 06:04; UTC

Uždarbis

Roche Expects 2025 Sales Increase in Mid Single Digit Range at Constant Currency

2025-01-30 06:04; UTC

Uždarbis

Roche Issues 2025 View

2025-01-30 06:03; UTC

Uždarbis

Roche Raises Dividend to CHF9.70 Vs CHF9.60

2025-01-30 06:03; UTC

Uždarbis

Roche 2024 Core Operating Profit CHF20.82B

2025-01-30 06:03; UTC

Uždarbis

Roche 2024 Net Pft CHF9.19B

2025-01-30 06:02; UTC

Uždarbis

Analysts Saw 2024 Core EPS at CHF18.59

2025-01-30 06:02; UTC

Uždarbis

Roche 2024 Core EPS CHF18.80

2025-01-30 06:02; UTC

Uždarbis

Roche 2024 Sales EUR60.50B

2025-01-30 06:02; UTC

Uždarbis

Analysts Saw Roche 2024 Revenue at CHF60.41B

2025-01-30 06:01; UTC

Uždarbis

Roche 2024 Sales CHFB

2025-01-28 10:30; UTC

Svarbiausios naujienos

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

2025-01-28 07:24; UTC

Rinkos pokalbiai

Roche's Breast Cancer Drug Extends Life of Patients -- Market Talk

2025-01-15 10:22; UTC

Rinkos pokalbiai

Swiss Companies Pay Record Level of Dividends as Buybacks Fall -- Market Talk

2025-01-08 06:15; UTC

Įsigijimai, susijungimai, perėmimai

Roche: 66.11% of Poseida's Shares Were Validly Tendered in Offer

2025-01-08 06:12; UTC

Įsigijimai, susijungimai, perėmimai

Roche Intends to Complete Acquisition of Poseida Therapeutics Later Wednesday

2024-12-16 22:03; UTC

Svarbiausios naujienos

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

2024-12-13 16:36; UTC

Rinkos pokalbiai

Swiss Equities an Overweight Pick Next Year -- Market Talk

2024-11-26 16:10; UTC

Įsigijimai, susijungimai, perėmimai

Why This Gene-Therapy Company's Stock Is Rising 228% -- Barrons.com

Roche Holding AG Prognozė

Rinkos nuotaikos

By Acuity

67 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.